Return on Equity: The amount of net income returned as a percentage of shareholders equity. Return on equity measures a corporation's profitability by revealing how much profit a company generates with the money shareholders have invested. Calculated as: Income from Continuing Operations / Total Common Equity
Immunovant, Inc. (IMVT) had Return on Equity of -11.22% for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
-- |
|
$-110.64M |
|
-- |
|
-- |
|
$114.36M |
|
$-114.36M |
|
$5.28M |
|
$-109.08M |
|
$-109.08M |
|
$-110.64M |
|
$-110.64M |
|
$-110.64M |
|
$-110.64M |
|
$-114.36M |
|
$-114.26M |
|
181.51M |
|
181.51M |
|
$-0.61 |
|
$-0.61 |
|
| Balance Sheet Financials | |
$1.04B |
|
$0.53M |
|
$9.45M |
|
$1.05B |
|
$66.26M |
|
-- |
|
-- |
|
$66.26M |
|
$986.13M |
|
$986.13M |
|
$986.13M |
|
203.32M |
|
| Cash Flow Statement Financials | |
$-312.25M |
|
-- |
|
$592.12M |
|
$713.97M |
|
$994.52M |
|
$280.55M |
|
$44.58M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
15.74 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-312.25M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
|
Return on Equity |
-11.22% |
-11.22% |
|
-10.51% |
|
-11.22% |
|
$4.85 |
|
$-1.72 |
|
$-1.72 |
|